In addition, patients with both ASXL1 and SRSF2 mutations had unique genetic characteristics and worse survival than patients with ASXL1 mutation only, SRSF2 mutation only, and neither (3 323 treatment-naive MDS samples [9], Supplementary Table S2, Fig. 1B, Supplementary Fig. 1A). The gene discussed is ASXL1; the disease is myelodysplastic syndrome.